Doorgaan naar hoofdcontent

Human medicines European public assessment report (EPAR): Rybrevant, amivantamab, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 09/12/2021, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Rybrevant, amivantamab, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 09/12/2021, Revision: 2, Status: Authorised